Rezvilutamide (SHR-3680)
Revision as of 23:38, 29 September 2022 by Jwarner (talk | contribs) (Created page with "==Mechanism of action== A nonsteroidal antiandrogen. ==Preliminary data== ===Prostate cancer=== #'''CHART:''' Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chon...")
Mechanism of action
A nonsteroidal antiandrogen.
Preliminary data
Prostate cancer
- CHART: Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022 Sep 5. Epub ahead of print. link to original article PubMed NCT03520478
Also known as
- Code name: SHR3680